SEARCH SITE
VIRGINIA LAW PORTAL
- Code of Virginia
- Virginia Administrative Code
- Constitution of Virginia
- Charters
- Authorities
- Compacts
- Uncodified Acts
- RIS Users (account required)
SEARCHABLE DATABASES
- Bills & Resolutions
session legislation - Bill Summaries
session summaries - Reports to the General Assembly
House and Senate documents - Legislative Liaisons
State agency contacts
ACROSS SESSIONS
- Subject Index: Since 1995
- Bills & Resolutions: Since 1994
- Summaries: Since 1994
Developed and maintained by the Division of Legislative Automated Systems.
2017 SESSION
Be it enacted by the General Assembly of Virginia:
1. That § 54.1-2522.1, as it is currently effective, of the Code of Virginia is amended and reenacted as follows:
§ 54.1-2522.1. (Effective until July 1, 2019) Requirements of prescribers.
A. Any prescriber who is licensed in the Commonwealth to treat human patients and is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription for a covered substance shall be registered with the Prescription Monitoring Program by the Department of Health Professions.
B. A prescriber registered with the Prescription Monitoring
Program or a person to whom he has delegated authority to access information in
the possession of the Prescription Monitoring Program pursuant to § 54.1-2523.2
shall, at the time of initiating a new course of treatment to a human patient
that includes the prescribing of opioids anticipated at the onset of treatment
to last more than 14 seven consecutive days, request information
from the Director for the purpose of determining what, if any, other covered
substances are currently prescribed to the patient. In addition, any prescriber
who holds a special identification number from the Drug Enforcement Administration
authorizing the prescribing of controlled substances approved for use in opioid
addiction therapy shall, prior to or as a part of execution of a treatment
agreement with the patient, request information from the Director for the
purpose of determining what, if any, other covered substances the patient is
currently being prescribed. Nothing in this section shall prohibit prescribers
from making additional periodic requests for information from the Director as
may be required by routine prescribing practices.
C. A prescriber shall not be required to meet the provisions of subsection B if:
1. The opioid is prescribed to a patient currently receiving hospice or palliative care;
2. The opioid is prescribed to a patient as part of treatment
for a surgical or invasive procedure and such prescription is not refillable
for no more than 14 consecutive days;
3. The opioid is prescribed to a patient during an inpatient hospital admission or at discharge;
4. The opioid is prescribed to a patient in a nursing home or a patient in an assisted living facility that uses a sole source pharmacy;
5. The Prescription Monitoring Program is not operational or available due to temporary technological or electrical failure or natural disaster; or
6. The prescriber is unable to access the Prescription Monitoring Program due to emergency or disaster and documents such circumstances in the patient's medical record.
2. That the second enactment of Chapter 113 and the second enactment of Chapter 406 of the Acts of Assembly of 2016 are amended and reenacted as follows:
2. That the provisions of this act shall expire on July 1,
2019 2022.
3. That the provisions of the first enactment of this act shall expire on July 1, 2022.